For example, the third-generation EGFR-TKI, osimertinib (AZD9291) was approved by the FDA for the treatment of EGFR-TKIs-acquired T790M resistance NSCLC in 2015, followed by a report in 2016 about the fourth-generation targeted drug EAI045 that overcomes AZD9291 resistance36. Here, EGFR is linked to non-small cell lung carcinoma.